Ann: Annual General Meeting Chairmans Address, page-3

Nice confident and assured AGM address........they have really acheived some solid outcomes in this last yr re product development......

Here's the main reasons I'm confident about BOT (despite the recent price movements)......

In relation to CBD:

"Botanix remains the ONLY company undertaking well-controlled FDA regulated studies in skin disease and now leads this research area globally. Matt and our Executive Board Director, Bill Bosch, have been in dialogue with an increasing number of strategic players given the growing interest and feedback on Botanix programs have been very positive to date"...........

and secondly funding:

"With a bit more than A$14 million in the bank at the end of September and expecting another A$4 million in R&D tax returns in the coming month, we are well funded to execute on our plans in the coming 12 months".............

thirdly:

"we’ve generated revenue to help offset our costs and hope to convert some of those projects into license arrangements in the course of 2019"....

Can't really expect too much more than what they have delivered in this last 12 months by my reckoning........the next 12 months here are going to be an exciting time.